Passage Bio, Inc. Common Stock (PASG) Stock Price
PASGStock
$4.52−34.49%52W
Market Cap$14.54M
P/E—
PEG Ratio—
Div yield—
Beta1.42
PASG Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-63.22%
Price vs S&P 500 (4W)-0.87%
VGM Score32.68
PASG Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$2.83 | -$2.44 | +13.93%(+$0.40) | |
| Q4 2025 | -$2.80 | -$4.09 | -46.28%(-$1.29) | |
| Q3 2025 | -$2.84 | -$2.44 | +14.08%(+$0.40) | |
| Q2 2025 | -$4.15 | -$2.96 | +28.67%(+$1.19) |
PASG Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
3.83
3.91
3.89
3.89
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PASGPassage Bio, Inc. Common Stock | — | — | D | $4.52 |
| AMGNAmgen Inc | C | C | B | $432.42 |
| GILDGilead Sciences Inc | C | B | B | $145.68 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1023.21 |
| MRNAModerna, Inc. Common Stock | D | C | A | $137.99 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $207.88 |
| BIIBBiogen Inc. Common Stock | C | D | B | $218.50 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $102.08 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $154.06 |
| EXELExelixis Inc | C | B | B | $54.45 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $105.35 |
About Passage Bio, Inc. Common Stock
Passage Bio develops genetic medicines for rare monogenic CNS disorders, including GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The company targets the underlying causes of these neurodegenerative conditions to address significant unmet medical needs.